SNS-301 (noninfectious lambda bacteriophage viruses)

Source Web search
Organization Sensei Biotherapeutics
Website URL senseibio.com
Market status Under Development
Industry Medical
Value chain stage Input
Business models B2C
Product categories Medical Treatment + Medicine
Biotech components Virus
Organization type(s) Private Company
Funding types Private Funding
Known funding amount $28,500,000 USD
Notes “Sensei Biotherapeutics has raised $28.5 million to advance a pipeline of personalized cancer drugs. The financing round comes weeks after Sensei shared clinical data on the effect of combining its lead asset SNS-301 with Merck’s checkpoint inhibitor Keytruda...SNS-301 is the most advanced example of Sensei’s immunophage approach. Sensei is engineering noninfectious lambda bacteriophage viruses to display target antigens. Upon entering an antigen-presenting cell, phage virions trigger a response that leads activated T cells to target the displayed tumor-associated antigen (TAA). Sensei plans to make personalized therapies out of off-the-shelf components, cutting the time it takes to deliver a treatment tailored to a patient’s tumor."
Added 3 years ago
Last modified 3 years ago